Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lymphoma: Mantle Cell

Join Amir Behdad, MD and Leo Gordon, MD as they present their multidisciplinary expertise on a range of cases pertaining to mantle cell lymphoma.

Mantle cell lymphoma (MCL) is a less common subtype of non-Hodgkin’s lymphoma characterized by the reciprocal chromosomal translocation t(11;14), resulting in the overexpression of cyclin D1. Cyclin D1-negative cases of MCL lacking t(11;14)have also been reported through gene expression pro?ling. The pathologic and clinical characteristics of cyclin D1-negative MCL appear to be similar to those of cyclin D1-positive cases.

MCL is thought to possess the worst characteristics of both indolent and aggressive NHL subtypes owing to the incurability of disease with conventional chemotherapy and a more aggressive disease course. Early stage localized disease at presentation is extremely rare and evidence for the management of this group of patients is very scarce. Radiation therapy (RT) with or without systemic therapy is a reasonable approach for the few patients presenting with early stage disease. The majority of patients diagnosed with MCL present with advanced stage disease requiring systemic therapy, although in highly selected cases “watch and wait” approach may be an option. The addition of rituximab to chemotherapy has resulted in durable complete remissions in newly diagnosed patients. However, there is lack of definitive data to recommend specific regimens for the management of patients with MCL.

Target Audience

This educational activity is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Apply NCCN Guideline-based therapeutic strategies for the treatment of patients with mantle cell lymphoma
  • Describe the multidisciplinary aspects of the management of patients with mantle cell lymphoma
  • Identify the key characteristics of  mantle cell lymphoma that trigger decision points
  • Recognize situations where optimal care may require adapting the Guideline recommendations to individual circumstances
Additional information
Supporters: 

Supported by educational grants from:

  • AstraZeneca
  • Exelixis Inc.
  • Genentech BioOncology
  • Janssen Biotech, Inc.
  • Novartis Oncology
  • Takeda Oncology

Supported by a grant from Onyx Pharmaceuticals.

Supported by independent educational grants from Merck and Prometheus Laboratories Inc.

Supported by an unrestricted, educational grant from Celgene Corporation.

Course summary
Available credit: 
  • 0.75 Participation
  • 0.73 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
03/20/2015
Course expires: 
03/20/2016
Cost:
$0.00

Amir Behdad, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Leo Gordon, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Available Credit

  • 0.75 Participation
  • 0.73 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician

Accreditation Period

Course opens: 
03/20/2015
Course expires: 
03/20/2016

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • For Windows: JavaScript and cookies enabled, Active X enabled and unblocked for Microsoft Internet Explorer, Java 6.0 or above
  • For Mac: JavaScript and cookies enabled, Plug-ins enabled in Safari, Java 6.0 or above
  • Adobe Reader or other PDF reader software for certificate viewing/printing